Esperion to Report Third Quarter 2025 Financial Results on November 6

Core Insights - Esperion will report its third quarter 2025 financial results on November 6, 2025, before market opens, followed by a management webcast at 8:00 a.m. ET to discuss the results and provide business updates [1][2] Company Overview - Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients at risk for cardiovascular disease with elevated LDL-C levels, supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients [3] - Esperion is advancing its next-generation program focused on ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design to create potent and specific inhibitors [3][4] Business Development - Esperion is evolving into a leading global biopharmaceutical company through effective commercial execution, international partnerships, collaborations, and the advancement of its pre-clinical pipeline [4]